These approvals not only broaden our hospital- and retail-focused range but also ensure you have reliable, ready-to-order therapies when and where patients need them. What’s New in Your Catalogue: 1 - Iohexol Injection – Advanced Diagnostic Imaging Now available for CT scans, angiography, myelography, body-cavity exams, and contrast-enhanced mammography, Iohexol gives radiology departments a single, trusted medium, so you can cut down on supplier complexity and keep imaging schedules on track. 2 - Ranolazine Elara Prolonged-Release Tablets – Stable Angina Relief As an add-on for patients whose angina is not fully managed by beta-blockers or calcium antagonists, these tablets help cardiology teams expand their treatment options without juggling multiple dossier submissions. 3 - Paracetamol Capsules – Fast-Acting Analgesic & Antipyretic From migraine relief to post-operative fever control, adding these capsules to your formulary means pharmacy teams can consolidate low-risk pain and fever management into a single, fully authorised product. Seamless Supply, Stronger Tenders By building on our existing UK portfolio, you benefit immediately from: Consistent Availability: All three products are ready to ship, with no back-order worries Tender-Ready Documentation: Our proven MHRA dossiers simplify your bid submissions, helping you hit every deadline with confidence. One Partner, Broader Coverage: Fewer vendors to manage across ICU, cardiology, and imaging, streamlining your procurement and logistics. Looking Ahead: In line with our commitment to support the NHS and drive operational resilience, we have submitted two more hospital-focused therapies through MHRA’s fast-track reliance pathway so Farmak International can bring essential treatments on board quickly in our next tender rounds and bolster patient care capacity. [press_quote] Next Steps: Ready to add these therapies to your offering? Email our UK team: info@farmak.uk Explore the full line-up: Products UK - FARMAK International
